Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1h-pyrrole-3-carboxylic Acid (2-diethylaminoethyl)amide
2. Su 011248
3. Su 11248
4. Su-011248
5. Su-11248
6. Su011248
7. Su11248
8. Sunitinib
9. Sutent
1. 341031-54-7
2. Sutent
3. Su011248 L-malate Salt
4. Sunitinib Malate [usan]
5. Pha-290940ad
6. Su010398
7. Sunitinib L-malate
8. Su-011248 L-malate Salt
9. Lvx8n1ut73
10. Su-010398
11. (z)-n-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide (s)-2-hydroxysuccinate
12. Su 11248
13. N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic Acid
14. Butanedioic Acid, Hydroxy-, (2s)-, Compd. With N-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide (1:1)
15. N-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide (2s)-hydroxybutanedioate
16. (2s)-2-hydroxybutanedioic Acid; N-[2-(diethylamino)ethyl]-5-{[(3z)-5-fluoro-2-oxo-2,3-dihydro-1h-indol-3-ylidene]methyl}-2,4-dimethyl-1h-pyrrole-3-carboxamide
17. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide (1:1)
18. Su 011248
19. Unii-lvx8n1ut73
20. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide (1:1)
21. Mfcd08282795
22. Pdgf Tk Antagonist
23. Sutent (tn)
24. Sunitinib Malate- Bio-x
25. Sutent (tn) (pfizer)
26. Sunitinib Malate (sutent)
27. Chembl1567
28. Su 11248 (malate)
29. Su-11248 L-malate Salt
30. Sunitinib Malate [mi]
31. Sunitinib Malate (jan/usan)
32. Sunitinib Malate [jan]
33. Schembl1258610
34. Schembl1772213
35. Dtxsid4046492
36. Sunitinib Malate [vandf]
37. Sunitinib Malate [mart.]
38. Pnu-290940ad
39. Sunitinib Malate [who-dd]
40. Hms3261h09
41. Sunitinib Malate, >=98% (hplc)
42. Tox21_500514
43. Nsc736511
44. S1042
45. Su-11248j
46. Akos005145765
47. Akos025149097
48. Sunitinib Malate (sunitinib L-malate)
49. Sunitinib Malate [orange Book]
50. Ccg-221818
51. Cs-0177
52. Ks-5023
53. Ncgc00261199-01
54. Bs164428
55. Hy-10255
56. Am20090634
57. Sw219407-1
58. D06402
59. 031s547
60. A822079
61. J-019449
62. Q27283213
63. Sunitinib Malate
64. 341031-54-7
65. Sutent
66. Su-11248
67. Sunitinib
68. (2s)-2-hydroxybutanedioic Acid Compd. With N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide (1:1)
69. (z)-n-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide(s)-2-hydroxysuccinate
70. 1h-pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-, (2s)-hydroxybutanedioate (1:1)
71. 1h-pyrrole-3-carboxamide,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-, (2s)-hydroxybutanedioate (1:1)
72. 1h-pyrrole-3-carboxamide,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-, Malate Salt
73. Butanedioic Acid, (2s)-, Compd. With N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide (1:1)
74. Butanedioic Acid, (2s)-, Compd. With N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide (1:1) (ca Index Name)
75. N-(2-diethylamino)ethyl)-5-((z)-(5-fluoro-2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide Hydrogen (2s)-2-hydroxybutanedioate
76. N-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidine)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide (2s)-2-hydroxybutanedioate Salt
Molecular Weight | 532.6 g/mol |
---|---|
Molecular Formula | C26H33FN4O7 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 10 |
Exact Mass | 532.23332757 g/mol |
Monoisotopic Mass | 532.23332757 g/mol |
Topological Polar Surface Area | 172 Ų |
Heavy Atom Count | 38 |
Formal Charge | 0 |
Complexity | 765 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Sunitinib malate |
Drug Label | SUTENT, an oral multi-kinase inhibitor, is the malate salt of sunitinib. Sunitinib malate is described chemically as Butanedioic acid, hydroxy-, (2S)-, compound with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)meth... |
Active Ingredient | Sunitinib malate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 12.5mg base; eq 25mg base; eq 37.5mg base |
Market Status | Prescription |
Company | Mylan Pharms |
2 of 2 | |
---|---|
Drug Name | Sunitinib malate |
Drug Label | SUTENT, an oral multi-kinase inhibitor, is the malate salt of sunitinib. Sunitinib malate is described chemically as Butanedioic acid, hydroxy-, (2S)-, compound with N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)meth... |
Active Ingredient | Sunitinib malate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 12.5mg base; eq 25mg base; eq 37.5mg base |
Market Status | Prescription |
Company | Mylan Pharms |
* Gastrointestinal stromal tumour (GIST):
Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance.
* Metastatic renal cell carcinoma (MRCC):
Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.
* Pancreatic neuroendocrine tumours (pNET):
Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults.
Experience with Sutent as first-line treatment is limited (see section 5. 1).
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01EX01
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-11-23
Pay. Date : 2012-11-13
DMF Number : 23414
Submission : 2009-12-29
Status : Active
Type : II
Lee Fine Chem: Advancing Innovation and Quality in Intermediates, APIs, and Dosage Forms for Superior Pharmaceutical Solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29653
Submission : 2021-04-21
Status : Active
Type : II
Date of Issue : 2022-07-27
Valid Till : 2025-07-02
Written Confirmation Number : WC-0147
Address of the Firm :
NDC Package Code : 82920-037
Start Marketing Date : 2023-09-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-12-27
Pay. Date : 2018-10-29
DMF Number : 33085
Submission : 2018-09-19
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-10-28
Pay. Date : 2022-09-23
DMF Number : 29014
Submission : 2015-03-04
Status : Active
Type : II
Date of Issue : 2022-08-31
Valid Till : 2025-07-20
Written Confirmation Number : WC-0198N
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-02-23
Pay. Date : 2021-10-29
DMF Number : 36392
Submission : 2021-10-12
Status : Active
Type : II
Registration Number : 305MF10101
Registrant's Address : No. 77D & 116/117, KIADB Industrial Area, Jigani, Phase - 2, Anekal Taluk, Bangalore - 560105, India
Initial Date of Registration : 2023-08-30
Latest Date of Registration :
Date of Issue : 2024-05-20
Valid Till : 2027-07-15
Written Confirmation Number : WC-0327
Address of the Firm :
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Canada
Brand Name : AURO-SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 12.5MG
Packaging :
Approval Date :
Application Number : 2532190
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : AURO-SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number : 2532220
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : SUTENT
Dosage Form : CAPSULE
Dosage Strength : 12.5MG
Packaging : 28
Approval Date :
Application Number : 2280795
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : SUTENT
Dosage Form : CAPSULE
Dosage Strength : 25MG
Packaging : 28
Approval Date :
Application Number : 2280809
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : SANDOZ SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 12.5MG
Packaging :
Approval Date :
Application Number : 2532840
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : SANDOZ SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number : 2532883
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : TARO-SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 12.5MG
Packaging :
Approval Date :
Application Number : 2524058
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : TARO-SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 25MG
Packaging :
Approval Date :
Application Number : 2524066
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : TARO-SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number : 2524082
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
Brand Name : TEVA-SUNITINIB
Dosage Form : CAPSULE
Dosage Strength : 12.5MG
Packaging :
Approval Date :
Application Number : 2526204
Regulatory Info :
Registration Country : Canada
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
12
PharmaCompass offers a list of Sunitinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sunitinib manufacturer or Sunitinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sunitinib manufacturer or Sunitinib supplier.
PharmaCompass also assists you with knowing the Sunitinib API Price utilized in the formulation of products. Sunitinib API Price is not always fixed or binding as the Sunitinib Price is obtained through a variety of data sources. The Sunitinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A SUNITINIB MALEATE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of SUNITINIB MALEATE, including repackagers and relabelers. The FDA regulates SUNITINIB MALEATE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. SUNITINIB MALEATE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of SUNITINIB MALEATE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A SUNITINIB MALEATE supplier is an individual or a company that provides SUNITINIB MALEATE active pharmaceutical ingredient (API) or SUNITINIB MALEATE finished formulations upon request. The SUNITINIB MALEATE suppliers may include SUNITINIB MALEATE API manufacturers, exporters, distributors and traders.
click here to find a list of SUNITINIB MALEATE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A SUNITINIB MALEATE DMF (Drug Master File) is a document detailing the whole manufacturing process of SUNITINIB MALEATE active pharmaceutical ingredient (API) in detail. Different forms of SUNITINIB MALEATE DMFs exist exist since differing nations have different regulations, such as SUNITINIB MALEATE USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A SUNITINIB MALEATE DMF submitted to regulatory agencies in the US is known as a USDMF. SUNITINIB MALEATE USDMF includes data on SUNITINIB MALEATE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The SUNITINIB MALEATE USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of SUNITINIB MALEATE suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The SUNITINIB MALEATE Drug Master File in Japan (SUNITINIB MALEATE JDMF) empowers SUNITINIB MALEATE API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the SUNITINIB MALEATE JDMF during the approval evaluation for pharmaceutical products. At the time of SUNITINIB MALEATE JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of SUNITINIB MALEATE suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a SUNITINIB MALEATE Drug Master File in Korea (SUNITINIB MALEATE KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of SUNITINIB MALEATE. The MFDS reviews the SUNITINIB MALEATE KDMF as part of the drug registration process and uses the information provided in the SUNITINIB MALEATE KDMF to evaluate the safety and efficacy of the drug.
After submitting a SUNITINIB MALEATE KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their SUNITINIB MALEATE API can apply through the Korea Drug Master File (KDMF).
click here to find a list of SUNITINIB MALEATE suppliers with KDMF on PharmaCompass.
A SUNITINIB MALEATE written confirmation (SUNITINIB MALEATE WC) is an official document issued by a regulatory agency to a SUNITINIB MALEATE manufacturer, verifying that the manufacturing facility of a SUNITINIB MALEATE active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting SUNITINIB MALEATE APIs or SUNITINIB MALEATE finished pharmaceutical products to another nation, regulatory agencies frequently require a SUNITINIB MALEATE WC (written confirmation) as part of the regulatory process.
click here to find a list of SUNITINIB MALEATE suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing SUNITINIB MALEATE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for SUNITINIB MALEATE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture SUNITINIB MALEATE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain SUNITINIB MALEATE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a SUNITINIB MALEATE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of SUNITINIB MALEATE suppliers with NDC on PharmaCompass.
SUNITINIB MALEATE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of SUNITINIB MALEATE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right SUNITINIB MALEATE GMP manufacturer or SUNITINIB MALEATE GMP API supplier for your needs.
A SUNITINIB MALEATE CoA (Certificate of Analysis) is a formal document that attests to SUNITINIB MALEATE's compliance with SUNITINIB MALEATE specifications and serves as a tool for batch-level quality control.
SUNITINIB MALEATE CoA mostly includes findings from lab analyses of a specific batch. For each SUNITINIB MALEATE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
SUNITINIB MALEATE may be tested according to a variety of international standards, such as European Pharmacopoeia (SUNITINIB MALEATE EP), SUNITINIB MALEATE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (SUNITINIB MALEATE USP).